ArticlePloS one2026
Based on single-cell and transcriptome analysis of inflammatory pathway biomarkers and their molecular mechanisms in chronic obstructive pulmonary disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation in chronic obstructive pulmonary disease (COPD) presents significant therapeutic challenges. Our study employs integrated transcriptomic and single-cell analyses to identify inflammation-related biomarkers and elucidate their pathogenic mechanisms in COPD.
methodsTraining dataset GSE37768, validation dataset GSE239897, and single-cell dataset GSE249584 were retrieved from the GEO database. Inflammation-associated genes were screened from the GeneCards database. Differential expression analysis was employed to identify candidate genes, followed by machine learning approaches and expression validation to pinpoint key genes. Functional characterization of these key genes was conducted through Gene Set Enrichment Analysis (GSEA), immune infiltration profiling, molecular regulatory network construction, drug prediction, and GeneMANIA interaction analysis. Single-cell data analysis elucidated cellular heterogeneity and identified critical cell types. Pseudotime analysis was subsequently performed to investigate the roles of key genes throughout developmental trajectories within these critical cell types.
resultsTwelve candidate genes associated with COPD and inflammation were screened, followed by GO and KEGG enrichment analyses. Subsequently, Least Absolute Shrinkage and Selection Operator (LASSO) regression and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) modeling identified six candidate key genes. Among these, only CXCL12, CXCR4, GGT1, and VWF exhibited consistent expression patterns across both training and validation datasets, establishing them as key genes. Their diagnostic value was further validated by constructing an artificial neural network model. Immune infiltration analysis revealed aberrant basophil abundance in COPD. Single-cell analysis annotated 11 distinct cell types, with macrophages representing the sole cell type demonstrating significant abundance differences between COPD and control groups. Pseudotime trajectory analysis delineated nine differentiation states, wherein CXCR4 expression persisted throughout the cellular differentiation trajectory.
conclusionsThis study identified CXCL12, CXCR4, GGT1, and VWF as key genes in COPD pathogenesis. Macrophages constituted the only cell type exhibiting significant abundance alterations, with CXCR4 demonstrating persistent expression throughout macrophage differentiation trajectories. These findings provide valuable insights and suggest potential directions for developing precision therapeutic strategies for COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.